Atherosclerosis progression in HIV-infected patients can be controlled over time, coinciding with increased use of lipid-lowering agents and smoking cessation.
Early IMT changes in HIV warrant serial vascular monitoring; hypothesis-generating for risk-factor interventions in long-term control.
This study reported the changes in carotid intima-media thickness (IMT) during a 36-month period in 233 HIV-infected patients. Median IMT increased in the first 12 months and then decreased by month 36. The prevalence of treatment with lipid-lowering agents and protease inhibitor-free highly active antiretroviral therapy regimens increased, whereas smoking prevalence decreased. The progression of atherosclerosis in HIV-infected patients can be controlled. The impact of individual measures to reduce the cardiovascular risk should be evaluated further.
No takes yet. Share an insight, caveat, or question.
Thiébaut et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: